Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial | Zendy

Reading Paul J. | Zendy; Luce Anna K | Zendy; McKeith Ian G. | Zendy

Premium

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial

Author(s) -

Reading Paul J.,

Luce Anna K,

McKeith Ian G.

Publication year - 2001

Publication title -

movement disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.352

H-Index - 198

eISSN - 1531-8257

pISSN - 0885-3185

DOI - 10.1002/mds.1204

Subject(s) - rivastigmine , psychosis , psychiatry , parkinson's disease , cognition , psychology , medicine , open label , distress , schizophrenia (object oriented programming) , cognitive impairment , randomized controlled trial , dementia , disease , clinical psychology , donepezil

This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug. © 2001 Movement Disorder Society.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research